References
- Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308–1316.
- Frenk SM, Kit BK, Lukacs SL, Hicks LA, Gu Q. Trends in the use of prescription antibiotics: NHANES 1999–2012. J Antimicrob Chemother. 2016;71:251–256.
- FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. http://www.fda.gov/Drugs/DrugSafety/ucm365050.htm. Updated August 15, 2013. Accessed November 4, 2016.
- Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology. 2014;83:1261–1263.
- Harden RN, Oaklander AL, Burton AW, et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. Pain Med. 2013;14:180–229.
- Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf. 1995;13:343–358.
- Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J. 1994;87:869–874.
- Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother. 2001;35:1540–1547.
- Panas M, Karadima G, Kalfakis N, Vassilopoulos D. Hereditary neuropathy unmasked by levofloxacin. Ann Pharmacother. 2011;45:1312–1313.